By SRH
Use of government resources to promote Bill Gates; FDA approves Bill Gates’ ‘Replicon’ mRNA avian influenza vaccine. The Trump administration will undoubtedly approve. Trump appoints COVID-19-vaccinated cabinet members who support Operation Warp Speed.
President-elect Donald Trump paid a visit to Washington, D.C. today to ensure that the new Senate Majority Leader was the right man for the job, and to assure him that the Senate would approve the people he wanted in his administration by agreeing to “recess appointments,” which allow him to install his own appointees without going through the confirmation process.
The Biden-Harris administration’s U.S. Food and Drug Administration (FDA) has given the green light to advance a new “self-amplifying” mRNA “vaccine” for “bird flu.”
The new “vaccine” is being developed by Arcturus Therapeutics, a Bill Gates-funded company specializing in mRNA-based pharmaceuticals.
On Monday, Arcturus quietly announced that the FDA approved the company’s Investigational New Drug (IND) application for its ARCT-2304 “vaccine.”
ARCT-2304 is a self-amplifying mRNA (sa-mRNA) injection targeting the H5N1 avian influenza “bird flu” virus.
The “self-amplifying” or “replicon” mRNA shots contain the equipment needed to make more of itself once it enters cells.
The injections have been dubbed “replicon” vaccines because they are able to replicate inside the human body to produce more mRNA over time.
The Biden-Harris administration’s U.S. Food and Drug Administration (FDA) has given the green light to advance a new “self-amplifying” mRNA “vaccine” for “bird flu.”
The new “vaccine” is being developed by Arcturus Therapeutics, a Bill Gates-funded company specializing in mRNA-based pharmaceuticals.
On Monday, Arcturus quietly announced that the FDA approved the company’s Investigational New Drug (IND) application for its ARCT-2304 “vaccine.”
ARCT-2304 is a self-amplifying mRNA (sa-mRNA) injection targeting the H5N1 avian influenza “bird flu” virus.
The “self-amplifying” or “replicon” mRNA shots contain the equipment needed to make more of itself once it enters cells.
The injections have been dubbed “replicon” vaccines because they are able to replicate inside the human body to produce more mRNA over time.
The new technology has provoked a worldwide backlash from experts and concerned citizens.
Japan has just approved the rollout of Covid “replicon” mRNA “vaccines” for public use.
Japanese citizens fear they are being used as guinea pigs ahead of a global rollout of the injections.
The International Crisis Summit (ICS) took place in Tokyo, Japan, from September 24 to 28.
The ICS, previously known as the International COVID Summit, aims to inform the public about the new “replicon” mRNA “vaccines.”
Dr. Robert Malone, the creator of mRNA technology, participated in the event during his trip to Japan to engage with experts about the new injections.
Malone provided an account of the Japanese rally he attended, where 30,000 individuals voiced their opposition to replicon injections.
“I just returned from Tokyo, where a rally of 30,000 people took place in response to the impending deployment of self-replicating RNA vaccines,” Malone stated.
“Japan is serving as the test case for the world regarding this new technology.”
“The Japanese people refer to this as the third atomic bomb.”
A group of prominent Dutch scientists and virologists has made a concerning discovery regarding the new Gates-funded “self-amplifying mRNA” vaccines, as reported by Slay News.
Wageningen University & Research in the Netherlands states that “replicon vaccines” may heighten the risk of pathogenic viruses transmitting among humans.
In the meantime, a collective of Canadian physicians has raised a red flag to the public regarding the government’s intentions to authorize “replicon vaccines” in Canada as well.
According to Slay News, doctors are cautioning the public that Canadian government regulators are set to follow Japan’s lead and approve the “replicon” mRNA injections.
One doctor referred to the shots as the “next iteration of Frankenstein technology.”
Nonetheless, it was disclosed that worries regarding the injections are being significantly suppressed, resulting in individuals being unaware of the dangers linked to “replicon vaccines.”
The Arcturus trial, supported by the Biomedical Advanced Research and Development Authority (BARDA), seeks to evaluate the effectiveness of ARCT-2304 in preventing pandemic influenza and intends to recruit approximately 200 healthy adults throughout the United States.
In a press release, Joseph Payne, President & CEO of Arcturus Therapeutics, stated:
“Arcturus is collaborating with the U.S. government to get ready for the next pandemic, and obtaining clearance to advance into the clinic with our STARR® self-amplifying mRNA technology is a crucial step in this significant endeavor.”
